Skip to content
Press Releases

New Study Conducted by KGK Science and Unigen Demonstrates the Sleep-Enhancing Benefits of Maizinol®

London, ON – October 8, 2024 – KGK Science, is proud to announce the successful completion of a collaborative study with Unigen Inc. The clinical trial evaluated the effects of Maizinol®, a nutraceutical ingredient derived from the leaves of Zea mays L. (corn), on sleep quality in healthy adults experiencing difficulty falling or staying asleep.

 

The randomized, triple-blind, placebo-controlled study enrolled 80 healthy participants and employed a gold-standard tool electroencephalogram (EEG) devices to assess sleep parameters. Conducted over a 28-day period, the study investigated the safety and efficacy of 500 mg of Maizinol®, administered daily 60 minutes before bedtime.

 

Key findings from the study include:

 

 

Dr. Erin D. Lewis, Scientific Director at KGK Science, emphasized the importance of the study, stating, “Conducting gold-standard clinical studies with objective tools like EEG to investigate sleep quality is critical to further our understanding of the complex interactions between natural health products and improvements in sleep.”

 

Maizinol® is a naturally occurring compound structurally similar to melatonin and has shown a strong affinity for melatonin receptors, stimulating melatonin synthesis. This trial builds upon previous findings, confirming Maizinol®’s efficacy in improving both objective and subjective sleep measures, all while being safe and well-tolerated by participants.

 

Unigen’s Chief Scientific Officer, Dr. Qi Jia, commented, “This study represents a critical step in providing consumers with scientifically backed, safe sleep support. The use of objective measurements like actigraphy and EEG raises the bar in the nutritional industry, providing a more accurate understanding of how sleep-support ingredients can truly benefit consumers.”

 

google-site-verification=ODzIjcIVmduDgyhTx98JdCy2M5Br0YEsotjjaj0hZbI